Revolutionizing Healthcare: The Trio of Scientists Recognized for Game-Changing GLP-1 Research
In 2024, three scientists were recognized by Time Magazine as among the 100 most influential people in the world: Professor Daniel Joshua Drucker, Professor Joel Francis Habener, and Associate Professor Svetlana Mojsov. The professors were honored for their collective efforts in researching and developing effective weight loss drugs.
Their work on diabetes drugs led to the identification of a crucial link between insulin and incretins, specifically GLP-1, which plays a key role in controlling blood sugar levels and weight. In December 2023, at the VinFuture Awards season 3, these scientists were awarded a special prize for their groundbreaking work on GLP-1. This research has resulted in the development of drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.
Associate Professor Svetlana Mojsov played a significant role in synthesizing GLP-1 and developing antibodies against it for crucial research. Her contributions have been instrumental in advancing our understanding of GLP-1 and its impact on insulin levels.
The use of GLP-1-based drugs has been approved in the US for treating diabetes and obesity, with potential applications in reducing the risk of cardiovascular diseases. Ongoing research is exploring further uses of these drugs in combating Alzheimer’s disease, Parkinson’s disease, kidney diseases, and liver disease.
The recognition of Associate Professor Svetlana Mojsov by Time Magazine underscores the importance of her pioneering work in the field of weight loss drugs, which was previously overlooked by major international biomedical awards. This acknowledgment aligns with the comprehensive evaluation criteria of the VinFuture Award, highlighting the groundbreaking contributions of these scientists.
In addition to the accolades from Time Magazine, these researchers have received numerous other awards for their revolutionary work on GLP-1. Their dedication to scientific research and innovation continues to shape the future of healthcare.
Overall, this group of scientists has made significant advancements in understanding how GLP-1 impacts insulin levels and weight control. Their work has led to new treatments for various diseases such as diabetes and obesity but also opens up possibilities for future treatments for Alzheimer’s disease
